Key result
In-hospital GDMT intensification is linked to a ~10% lower risk of death or HHF.
Why the study?
The real-world impact of in-hospital intensification of guideline-directed medical therapy on long-term clinical outcomes in patients hospitalized for heart failure remains uncertain.
Does in-hospital intensification of guideline-directed medical therapy reduce the composite outcome of all-cause death or heart failure hospitalization in patients hospitalized for worsening heart failure?
Cohort (n=3,190)
Yes
Does in-hospital intensification of guideline-directed medical therapy reduce the composite outcome of all-cause death or heart failure hospitalization in patients hospitalized for worsening heart failure?
Answers are grounded in this paper and cite their sources.
Intensifying guideline-directed medical therapy during a heart failure hospitalization is independently associated with significant improvements in long-term mortality and readmission outcomes, underscoring the hospital stay as a critical therapeutic window.
BACKGROUND: The real-world impact of in-hospital intensification of guideline-directed medical therapy (GDMT) on clinical outcomes in patients with heart failure (HF) remains uncertain. We evaluated the association between in-hospital GDMT intensification and long-term outcomes using data from the multicenter QHEART-R cohort. METHODS AND RESULTS: We analyzed 3,190 patients hospitalized for worsening HF. In-hospital GDMT intensification was quantified by the change in the simple GDMT score from admission to discharge (∆S-GDMT). The primary outcome was a composite of all-cause death or hospitalization for HF (HHF). The mean (±SD) age of the cohort was 77.7±14.0 years, 53% were male, and the mean hospital stay was 20±16 days. The cohort included 1,477 (46%) patients with HF with reduced ejection fraction (HFrEF), 435 (14%) with HF with mildly reduced ejection fraction (HFmrEF), and 1,276 (40%) with HF with preserved ejection fraction. Four-year event-free survival was 32.4% for the primary outcome, 82.5% for cardiovascular (CV) death, and 50.4% for HHF. In patients with HFrEF/HFmrEF, a greater ∆S-GDMT was independently associated with a lower risk of the primary outcome (adjusted hazard ratio 0.90; 95% confidence interval 0.86-0.93; P<0.001), regardless of the number of prior HHF or the simple GDMT score at discharge. CONCLUSIONS: In-hospital GDMT intensification was associated with improved long-term outcomes in patients with HFrEF/HFmrEF. Hospitalization represents a critical opportunity to optimize GDMT and improve prognosis.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2026) conducted a cohort in Worsening heart failure (n=3,190). In-hospital guideline-directed medical therapy (GDMT) intensification (∆S-GDMT) vs. Lower or no GDMT intensification was evaluated on Composite of all-cause death or hospitalization for heart failure (HHF) (HR 0.90, 95% CI 0.86-0.93, p=<0.001). In patients with HFrEF or HFmrEF, greater in-hospital intensification of guideline-directed medical therapy was independently associated with a lower risk of all-cause death or heart failure hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: